Cyclooxygenase 2 inhibition in patients with non–small cell lung cancer: Is this still a valid target for therapy?

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|18|3197-3200

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.18, 2015-09, pp. : 3197-3200

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Chemotherapy in Non-Small Cell Lung Cancer Patients Receiving Oxygen Therapy

By  

Oncology Research and Treatment, Vol. 39, Iss. 10, 2016-09 ,pp. : 587-590

Karger

Access to resources Recommend Favorite

Concomitant Chemoradiotherapy and Antiretroviral Therapy for HIV-Infected Patients with Locoregionally Advanced Non-Small Cell Lung Cancer: Benefit and Tolerability of Treatment in 2 Cases

By  

Oncology Research and Treatment, Vol. 36, Iss. 10, 2013-09 ,pp. : 586-590

Karger

Access to resources Recommend Favorite

Epidermal Growth Factor Receptor Inhibition and Non-Small Cell Lung cancer

By von Eyben Finn  

Critical Reviews in Clinical Laboratory Sciences, Vol. 43, Iss. 4, 2006-08 ,pp. : 291-323

Informa Healthcare

Access to resources Recommend Favorite

The Role of EGFR-TK Inhibition in Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 28, Iss. 12, 2005-12 ,pp. : 619-620

Karger

Access to resources Recommend Favorite

Metabolic Response Assessment in Non-Small Cell Lung Cancer Patients after Platinum-Based Therapy: A Preliminary Analysis

By  

Current Medical Imaging Reviews, Vol. 11, Iss. 4, 2015-01 ,pp. : 218-227

Bentham Science Publishers

Access to resources Recommend Favorite